DeCODE Heart Attack Drug To Return To Phase III With Expanded Study Population
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
DeCODE Genetics has expanded the patient population for its Phase III trial of its lead compound DG031 to include all patients who carry a variant of one of the genes the company has linked to risk of heart attack via the leukotriene pathway.